

Home Video News Images Health Education Topics Blogs Mobile

Space Science Technology Health General Sci-Fi & Gaming Oddities International Business Education Mars Science Laboratory Curiosity

Home » News » Health » Prix Galien USA Announces 2009 Final Candidates

### **Prix Galien USA Announces 2009 Final Candidates**

August 7, 2009

# Honorees for Best Pharmaceutical Agent, Best Biotechnology Product and Best Medical Technology to be recognized at Sept. 30 gala ceremony

NEW YORK, Aug. 7 /PRNewswire-USNewswire/ — The 2009 Prix Galien USA will recognize innovative biopharmaceutical drugs and medical technologies that have made a deep impact on the quality of human life at a gala event on September 30. Candidates for the 2009 program provide relief to millions of people living with chronic diseases including cardiovascular disease and diabetes and treatments for people living with cancer and HIV/AIDS. The 2009 Prix Galien USA ceremony will again be emceed by Charlie Rose at the American Museum of Natural History in New York.

Final candidates for the Prix Galien USA 2009 awards are:

#### **Best Pharmaceutical Agent:**

AstraZeneca, CRESTOR(R)

Celgene, Vidaza(R)

Novartis Oncology, GLEEVEC(R)

Novartis Pharmaceuticals, EXELON(R)()PATCH

Pfizer, Zyvox(R)

Schering-Plough, TEMODAR(R) and ZETIA(R)

Teva Neurosciences, AZILECT(R)

Wyeth, TORISEL(R)

#### **Best Biotechnology Product:**

Amgen, Nplate(R)

GlaxoSmithKline, PROMACTA(R) and Tykerb(R)

Schering-Plough, PEGINTRON(R)

Tibotec, INTELENCE(TM)

United Therapeutics, REMODULIN(R)

Wyeth, Prevnar (R)

## Best Medical Device:

Abbott Vascular, XIENCE (R)

Boston Scientific, TAXUS (R)

DCA Design, Lantus(R)()SoloSTAR(R)

#### **Related Articles**

Nosebleeds Can Be an Early Warning Sign to More Serious Health Problems

HIV vaccines increase infection rates in primate study Researchers develop cheaper, easier method of detecting trace estrogen

"Death from cancer is the best," says doctor

Tired? You may have a magnesium deficiency

NASA Gets Budget Boost In \$1.1 Trillion Spending Bill

Is Natural Gas A 'Bridge' To A Hotter Future?

New Study Indicates That Increased Natural Gas Use Will Not Slow Climate Change

T-Mobile's Future Up In The Air After French Telecom Company Iliad Withdraws Takeover Bid

GT Advanced Technologies Files For Bankruptcy After Lost Apple Deal

Sanofi Exhibit 2142.001



of research and level of skill that was invested in the development of these products that improve lives," said Gerald Weissmann, M.D., Prix Galien USA committee chair, New York University professor emeritus and editor-in-chief of The FASEB Journal.

Prix Galien USA honorees are judged on the basis of the innovative nature of the development, application or clinical utility of the drug or technology and whether its discovery can be applied to future biomedical science.

In 2008, the Prix Galien USA committee recognized Selzentry(TM)() (Pfizer Inc.), Isentress(R) (Merck & Co., Inc.), Soliris(R) (Alexion Pharmaceuticals, Inc.), INFUSE(R) (Wyeth) and Revlimid(R)() (The Celgene Corporation).

The Prix Galien USA award is considered the industry's highest accolade for pharmaceutical research and development — equivalent to the Nobel Prize. The award committee comprises 11 individuals including seven Nobel Laureates, founders of major biotech companies and editors of world-renowned biology journals. For details about the Prix Galien USA award and committee visit <a href="https://www.prix-galien-usa.com">www.prix-galien-usa.com</a>.

SOURCE Prix Galien USA

Source: newswire

comments powered by Disqus



Sanofi Exhibit 2142.002